Spero Therapeutics, Inc. (SPRO) Form 8-K — Nov 10, 2026

$SPROForm 8-KItems 5.02Filed Nov 10, 2026, 5:30 PM ET0001193125-26-455789Original filing

Spero Therapeutics announced that director Patrick Vink, M.D. resigned from the Board effective November 10, 2026, after 11 years of service, and stated the resignation was not due to any dispute with the company. The Board appointed William Ho, M.D., Ph.D. to fill the vacancy.

Key figures

Director option grant shares: 100000
Director cash retainer annual usd: 40000
Development committee retainer annual usd: 5000

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.